New treatment option for spinal muscular atrophy moves closer to EU approval

48-month analysis shows delayed progression and reduced risk in early Alzheimer’s patients

AI platform to support biomarker-guided therapy development in MASH

US$5m payment from Bristol Myers Squibb marks progress in protein degradation partnership

Patent filed for AdoXLong with promising monthly injection potential

Findings highlight benefits in speech and daily activities alongside mental health stability

Enlicitide significantly reduces LDL-C in patients with high cardiovascular risk

Allo-iNKT cell therapy shows durable survival and immune restoration in PD-1–refractory tumours

New treatment option offers hope for children with nephropathic cystinosis

Lead ATAC candidate HDP-101 shows strong clinical activity and safety in phase 8 cohort